Ono Pharmaceutical Co., Ltd.

Ono Pharmaceuticalco.,ltd.

Shigeyuki Nonaka

Hiroshi Yamamoto

Atsushi Naganawa

Kensuke Kusumi

Tetsuya Sekiguchi

Akito Kakuuchi

Kazuhiro Otsuki

Koji Shinozaki

Takayuki Maruyama

The compound of the formula (I-1): wherein all the symbols have the same meanings as described in the specification, has two cyclic groups, particularly phenoxy groups at specific substitution positions and thus has high human S1Pantagonistic activity. The compound may therefore be used as a therapeutic agent for S1P-mediated diseases such as diseases resulting from vascular constriction, fibrosis, and respiratory diseases.

Phenyl derivative

The compound represented by the formula (I-1): wherein all the symbols have the same meanings as described in the specification, has two cyclic groups, particularly phenoxy groups at specific substitution positions and thus has high human S1Pantagonistic activity. The compound may therefore be used as a therapeutic agent for S1P-mediated diseases such as diseases resulting from vascular constriction, fibrosis and respiratory diseases.

A pharmaceutical composition for the treatment and/or prevention of depression comprising a compound having an antagonistic activity for EPreceptor which a prostaglandin Ereceptor subtype. EPantagonist is useful for the treatment of depression, for example, endogenous depression, reactive depression, weatherability depression, neurological depressed state, the depressed state of brain organic mental disorder.

Remedies for depression containing EP1 antagonist as the active ingredient

Growing community of inventors

Osaka, Japan

Shigeyuki Nonaka